Cell Cycle Associated MiRNAs As Target and Therapeutics in Lung Cancer Treatment

Overview

Journal Heliyon

Specialty Social Sciences

Date 2022 Oct 28

PMID 36303933

Authors

Atqiya Fariha

Ithmam Hami

Mahafujul Islam Quadery Tonmoy

Shahana Akter

Hasan Al Reza

Newaz Mohammed Bahadur

Md Mizanur Rahaman

Md Shahadat Hossain

Affiliations

Soon will be listed here.

Abstract

Lung cancer is the primary cause of cancer related deaths worldwide. Limited therapeutic options and resistance to existing drugs are the major hindrances to the clinical success of this cancer. In the past decade, several studies showed the role of microRNA (miRNA) driven cell cycle regulation in lung cancer progression. Therefore, these small nucleotide molecules could be utilized as promising tools in lung cancer therapy. In this review, we highlighted the recent advancements in lung cancer therapy using cell cycle linked miRNAs. By highlighting the roles of the specific cell cycle core regulators affiliated miRNAs in lung cancer, we further outlined how these miRNAs can be explored in early diagnosis and treatment strategies to prevent lung cancer. With the provided information from our review, more medical efforts can ensure a potential breakthrough in miRNA-based lung cancer therapy.

Citing Articles

Screening and analysis of single nucleotide polymorphism in the 3'-UTR microRNA target regions and its implications for lung tumorigenesis.

Bhatia A, Upadhyay A, Sharma S Pharmacogenomics. 2024; 25(7):299-314.

PMID: 38884942 PMC: 11404702. DOI: 10.1080/14622416.2024.2355864.

Identifying lncRNAs and mRNAs related to survival of NSCLC based on bioinformatic analysis and machine learning.

Yue W, Wang J, Lin B, Fu Y Aging (Albany NY). 2024; 16(9):7799-7817.

PMID: 38696317 PMC: 11131976. DOI: 10.18632/aging.205783.

FOXM1 promotes the progression of non-small cell lung cancer by inhibiting miR-509-5p expression via binding to the miR-509-5p promoter region.

Tian M, Li J, Wu H, Wu Y Heliyon. 2024; 10(5):e27147.

PMID: 38495135 PMC: 10943339. DOI: 10.1016/j.heliyon.2024.e27147.

miRNA-Based Technologies in Cancer Therapy.

Pagoni M, Cava C, Sideris D, Avgeris M, Zoumpourlis V, Michalopoulos I J Pers Med. 2023; 13(11).

PMID: 38003902 PMC: 10672431. DOI: 10.3390/jpm13111586.

MicroRNA-Mediated Regulation of Histone-Modifying Enzymes in Cancer: Mechanisms and Therapeutic Implications.

Szczepanek J, Tretyn A Biomolecules. 2023; 13(11).

PMID: 38002272 PMC: 10669115. DOI: 10.3390/biom13111590.

References

Yuwen D, Sheng B, Liu J, Wenyu W, Shu Y . MiR-146a-5p level in serum exosomes predicts therapeutic effect of cisplatin in non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 2017; 21(11):2650-2658. View

Hong D, Kang Y, Borad M, Sachdev J, Ejadi S, Lim H . Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer. 2020; 122(11):1630-1637. PMC: 7251107. DOI: 10.1038/s41416-020-0802-1. View

Chen K, Shi W . Autophagy regulates resistance of non-small cell lung cancer cells to paclitaxel. Tumour Biol. 2016; 37(8):10539-44. DOI: 10.1007/s13277-016-4929-x. View

Liu C, Hu W, Li L, Wang Y, Zhou Q, Zhang F . Roles of miR-200 family members in lung cancer: more than tumor suppressors. Future Oncol. 2018; 14(27):2875-2886. DOI: 10.2217/fon-2018-0155. View

Wang H, Zhao X, Guo C, Ren D, Zhao Y, Xiao W . Aptamer-Dendrimer Bioconjugates for Targeted Delivery of miR-34a Expressing Plasmid and Antitumor Effects in Non-Small Cell Lung Cancer Cells. PLoS One. 2015; 10(9):e0139136. PMC: 4583438. DOI: 10.1371/journal.pone.0139136. View

Cherni I, Weiss G . miRNAs in lung cancer: large roles for small players. Future Oncol. 2011; 7(9):1045-55. DOI: 10.2217/fon.11.74. View

Xie H, Chen J, Lv X, Zhang L, Wu J, Ge X . Clinical Value of Serum and Exhaled Breath Condensate miR-186 and IL-1β Levels in Non-Small Cell Lung Cancer. Technol Cancer Res Treat. 2020; 19:1533033820947490. PMC: 7457640. DOI: 10.1177/1533033820947490. View

He Z, Liu Y, Xiao B, Qian X . miR-25 modulates NSCLC cell radio-sensitivity through directly inhibiting BTG2 expression. Biochem Biophys Res Commun. 2015; 457(3):235-41. DOI: 10.1016/j.bbrc.2014.12.094. View

De Ruysscher D, van Baardwijk A, Steevens J, Botterweck A, Bosmans G, Reymen B . Individualised isotoxic accelerated radiotherapy and chemotherapy are associated with improved long-term survival of patients with stage III NSCLC: a prospective population-based study. Radiother Oncol. 2011; 102(2):228-33. DOI: 10.1016/j.radonc.2011.10.010. View

10.

Bandi N, Zbinden S, Gugger M, Arnold M, Kocher V, Hasan L . miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res. 2009; 69(13):5553-9. DOI: 10.1158/0008-5472.CAN-08-4277. View

11.

Li J, Tan Q, Yan M, Liu L, Lin H, Zhao F . miRNA-200c inhibits invasion and metastasis of human non-small cell lung cancer by directly targeting ubiquitin specific peptidase 25. Mol Cancer. 2014; 13:166. PMC: 4105889. DOI: 10.1186/1476-4598-13-166. View

12.

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

13.

Nasser M, Datta J, Nuovo G, Kutay H, Motiwala T, Majumder S . Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J Biol Chem. 2008; 283(48):33394-405. PMC: 2586284. DOI: 10.1074/jbc.M804788200. View

14.

Cimmino A, Calin G, Fabbri M, Iorio M, Ferracin M, Shimizu M . miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005; 102(39):13944-9. PMC: 1236577. DOI: 10.1073/pnas.0506654102. View

15.

Carthew R, Sontheimer E . Origins and Mechanisms of miRNAs and siRNAs. Cell. 2009; 136(4):642-55. PMC: 2675692. DOI: 10.1016/j.cell.2009.01.035. View

16.

Kozomara A, Birgaoanu M, Griffiths-Jones S . miRBase: from microRNA sequences to function. Nucleic Acids Res. 2018; 47(D1):D155-D162. PMC: 6323917. DOI: 10.1093/nar/gky1141. View

17.

Lei L, Huang Y, Gong W . miR-205 promotes the growth, metastasis and chemoresistance of NSCLC cells by targeting PTEN. Oncol Rep. 2013; 30(6):2897-902. DOI: 10.3892/or.2013.2755. View

18.

Yu S, Chen H, Chang G, Chen C, Chen H, Singh S . MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell. 2008; 13(1):48-57. DOI: 10.1016/j.ccr.2007.12.008. View

19.

Li J, Yu M, Liu Z, Liu B . Clinical significance of serum miR-25 in non-small-cell lung cancer. Br J Biomed Sci. 2019; 76(3):111-116. DOI: 10.1080/09674845.2019.1592915. View

20.

Fiori M, Barbini C, Haas T, Marroncelli N, Patrizii M, Biffoni M . Antitumor effect of miR-197 targeting in p53 wild-type lung cancer. Cell Death Differ. 2014; 21(5):774-82. PMC: 3978312. DOI: 10.1038/cdd.2014.6. View